No definition available.

Name:	isis_CollaborativeArrangementAndLicensingAgreementAbstract
Namespace Prefix:	isis_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the maximum amount of payments receivable under the agreement.

+ References

No definition available.

+ Details

Name:	isis_MaximumAmountOfPaymentsReceivable
Namespace Prefix:	isis_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the amount of near-term payments that can be received under the agreement.

+ References

No definition available.

+ Details

Name:	isis_NearTermPayments
Namespace Prefix:	isis_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The maximum percentage of gross margins of sales of the drug received as royalties under the collaborative arrangement.

+ References

No definition available.

+ Details

Name:	isis_PercentageOfGrossMarginsOfSalesReceivedAsRoyalties
Namespace Prefix:	isis_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the next prospective milestone payment to be earned.

+ References

No definition available.

+ Details

Name:	isis_ProspectiveMilestonePayment
Namespace Prefix:	isis_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Represents the amount of upfront fees received during the period under the agreement.

+ References

No definition available.

+ Details

Name:	isis_UpfrontFeeReceived
Namespace Prefix:	isis_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The portion of upfront fees received during the period under the terms of the agreement that are recognized as revenue during the period.

+ References

No definition available.

+ Details

Name:	isis_UpfrontFeeRecognized
Namespace Prefix:	isis_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6351-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13531-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6404-108592

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13537-108611

+ Details

Name:	us-gaap_ConcentrationRiskPercentage1
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name:	us-gaap_DeferredRevenueAdditions
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name:	us-gaap_Revenues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_CounterpartyNameAxis=isis_BayerHealthCareMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=isis_CollaborativeArrangementsAndLicensingAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=isis_AgreementEnteredIntoInMay2015Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	isis_AchievementOfMilestoneAxis=isis_LicenseFeesMilestonePaymentsAndOtherPaymentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	isis_AchievementOfMilestoneAxis=isis_DevelopmentMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	isis_AchievementOfMilestoneAxis=isis_CommercializationMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=isis_IsisFxiMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=isis_IsisFxiDevelopmentActivitiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaborative Arrangements and Licensing Agreements, Traditional Pharmaceutical Alliances and Licensing - Bayer HealthCare (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
	May. 31, 2015	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Collaborative Arrangement and Licensing Agreement [Abstract]
Revenue earned		$ 120,428	$ 57,076	$ 183,012	$ 85,237
Bayer HealthCare [Member] \| Collaborations and Licensing Agreements [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Revenue earned		91,500		91,500
Deferred revenue		$ 8,500		$ 8,500
Bayer HealthCare [Member] \| Collaborations and Licensing Agreements [Member] \| Revenue [Member] \| Strategic Partner [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Concentration percentage		76.00%		50.00%
Bayer HealthCare [Member] \| Agreement Entered into in May 2015 [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Near-term payments	$ 155,000
Upfront fee received		$ 100,000
Next prospective milestone		55,000		$ 55,000
Bayer HealthCare [Member] \| Agreement Entered into in May 2015 [Member] \| Minimum [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Percentage of gross margins of sales received as royalties	20.00%
Bayer HealthCare [Member] \| Agreement Entered into in May 2015 [Member] \| License Fees, Substantive Milestone Payments and Other Payments [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Maximum amount of payments receivable		375,000		375,000
Bayer HealthCare [Member] \| Agreement Entered into in May 2015 [Member] \| Development Milestones [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Maximum amount of payments receivable		120,000		120,000
Bayer HealthCare [Member] \| Agreement Entered into in May 2015 [Member] \| Commercialization Milestones [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Maximum amount of payments receivable		110,000		$ 110,000
Bayer HealthCare [Member] \| Agreement Entered into in May 2015 [Member] \| ISIS-FXI [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Upfront fee recognized		91,200
Bayer HealthCare [Member] \| Agreement Entered into in May 2015 [Member] \| ISIS-FXI Development Activities [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Upfront fee recorded as deferred revenue		$ 8,800